Subscribe
shutterstock_1216100428_gral
GrAl / Shutterstock.com
3 June 2021Big PharmaAlex Baldwin

Clarus succeeds in invalidating four Lipocine testosterone patents

Clarus Therapeutics has convinced a US court to invalidate four Lipocine testosterone booster patents it was accused of infringing.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly sues Cipla for infringing testosterone patents
1 November 2016   Eli Lilly has filed a complaint against India-based drug company Cipla for allegedly infringing its patents covering Axiron.
Americas
Actavis loses testosterone patent case at Federal Circuit
17 October 2016   The US Court of Appeals for the Federal Circuit has affirmed a district court’s patent ruling in favour of global pharma company Endo and Scotland-based Strakan International in a case against Actavis.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Eli Lilly sues Cipla for infringing testosterone patents
1 November 2016   Eli Lilly has filed a complaint against India-based drug company Cipla for allegedly infringing its patents covering Axiron.
Americas
Actavis loses testosterone patent case at Federal Circuit
17 October 2016   The US Court of Appeals for the Federal Circuit has affirmed a district court’s patent ruling in favour of global pharma company Endo and Scotland-based Strakan International in a case against Actavis.

More on this story

Americas
Eli Lilly sues Cipla for infringing testosterone patents
1 November 2016   Eli Lilly has filed a complaint against India-based drug company Cipla for allegedly infringing its patents covering Axiron.
Americas
Actavis loses testosterone patent case at Federal Circuit
17 October 2016   The US Court of Appeals for the Federal Circuit has affirmed a district court’s patent ruling in favour of global pharma company Endo and Scotland-based Strakan International in a case against Actavis.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB